Initial digest — THRB receipt

what this node claims

Initial digest — THRB

AlphaFold v6 prediction landed for **THRB** (Thyroid hormone receptor beta). UniProt accession: `P10828`. Lane: `metabolic`. Mean per-residue pLDDT: **80.21**. Resmetirom-class liver-selective TRβ target.

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

80.2

461 residues / min 19.47 / max 98.81 / source alphafold db

Very high 69.2% 319 residues / >=90

Confident 7.6% 35 residues / 70-89

Low 2.0% 9 residues / 50-69

Very low 21.3% 98 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 461 of 461 residues.

residues 1-95 / mean 28.28
residues 254-262 / mean 51.51
residues 207-209 / mean 64.66

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — THRB